Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be a **multi-ingredient compounded procedural injection kit or admixture** built around **bupivacaine hydrochloride** as the local anesthetic plus **triamcinolone acetonide** and **dexamethasone sodium** as corticosteroid anti-inflammatory adjuvants; **isopropyl alcohol** is typically a skin antiseptic component supplied in procedure kits rather than an injected active therapeutic ingredient. Bupivacaine blocks voltage-gated sodium channels to inhibit peripheral nerve conduction and provide local anesthesia, while triamcinolone acetonide and dexamethasone act through the glucocorticoid receptor to suppress inflammatory signaling. Publicly visible sources strongly support related procedure kits containing bupivacaine, triamcinolone, and isopropyl alcohol, but I did not find a concrete public-source product or trial clearly verifying this exact four-component combination as a distinct marketed drug entity; accordingly this entry is best treated as a specific but poorly verified combination listing rather than a well-defined branded asset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isopropyl alcohol + bupivacaine hydrochloride + triamcinolone acetonide + dexamethasone sodium.